FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the medical pharmacology, in particular to the recombinant monoclonal antibody to TNFα (adalimumab) improved aqueous pharmaceutical compositions and to their preparation method. Invention also relates to the use recombinant monoclonal antibody to TNFα (adalimumab) improved aqueous pharmaceutical compositions for the TNFα mediated diseases treatment.
EFFECT: proposed invention allows to prevent the physic-chemical instability, expressed in the aggregates and protein fragments formation or proteins modification in the solution, and also prevents instability during the freezing and thawing, stirring and shaking.
22 cl, 9 dwg, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ADALIMUMAB | 2014 |
|
RU2664736C2 |
| PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND USE THEREOF | 2021 |
|
RU2791857C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2019 |
|
RU2754760C2 |
| PHARMACEUTICAL COMPOSITION OF ANTI-CD20 ANTIBODY AND USE THEREOF | 2022 |
|
RU2824627C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| METHOD FOR TREATMENT OF MALIGNANT NEOPLASM, USING COMBINATION OF ANTIBODY TO PD-1 AND CHEMOTHERAPEUTIC AGENT | 2021 |
|
RU2787457C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
